Genetic Technologies (Genetic Technologies) Debt-to-Equity

: 0.08 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

Genetic Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.20 Mil. Genetic Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.06 Mil. Genetic Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3.22 Mil. Genetic Technologies's debt to equity for the quarter that ended in Dec. 2023 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Genetic Technologies's Debt-to-Equity or its related term are showing as below:

GENE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 4.95
Current: 0.08

During the past 13 years, the highest Debt-to-Equity Ratio of Genetic Technologies was 4.95. The lowest was 0.00. And the median was 0.04.

GENE's Debt-to-Equity is ranked better than
76.14% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs GENE: 0.08

Genetic Technologies Debt-to-Equity Historical Data

The historical data trend for Genetic Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

0.03

0.01

0.04

0.05

Genetic Technologies Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.06	N/A	0.05	N/A	0.08

Competitive Comparison

For the Diagnostics & Research subindustry, Genetic Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Debt-to-Equity falls into.

Genetic Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Genetic Technologies's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.204	+	0.154)	/	7.492
	=	0.05

Genetic Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.199	+	0.056)	/	3.221
	=	0.08

Genetic Technologies (NAS:GENE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Genetic Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (Genetic Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.